Netherlands· NL-37e86c6640c9

Dificlir 40 mg/ml, granulaat voor orale suspensie

A fidaxomicin product containing fidaxomicine, registered in Netherlands by Tillotts Pharma GmbH. The same ATC class is registered in 16 of our 19 countries.

ATC A07AA12

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about fidaxomicineAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Fidaxomicin is registered in 16 of 19 countries.

Countries holding a registration under ATC A07AA12 (fidaxomicin), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search fidaxomicin products by name

Fidaxomicin · ATC A07AA12

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of fidaxomicin costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Fidaxomicin · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

CH Switzerland$179.87

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: FIDAXOMICINE
Manufacturer: Tillotts Pharma GmbH
Country: Netherlands (NL)
ATC code: A07AA12
ATC class: Fidaxomicin
Defined daily dose: 0.4 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/11/733

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

101 interactions on record for fidaxomicin.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check fidaxomicin against other medicines How interaction checks work

Fidaxomicin · interactions on record

101 records

3 severe
24 moderate
74 minor

Most severe, free to view

BerotralstatB06AC06severe
VenetoclaxL01XX52severe
RelugolixL02BX04severe
Sodium picosulfateA06AB08moderate

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fidaxomicin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fidaxomicin products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

France · Fidaxomicine Sun
United Kingdom (Northern Ireland) · Fidaxomicin Tillotts 200 Mg, Fidaxomicin Tillotts 40 Mg/Ml
Iceland · Dificlir
Liechtenstein · Dificlir, Dificlir 200 Mg
Norway · Dificlir, Dificlir 200 Mg
Sweden · Fidaxomicin Sun

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/0b3b01bb-4aa9-4f2d-b8b1-6c32fa6dbf40
GET /v1/drugs/0b3b01bb-4aa9-4f2d-b8b1-6c32fa6dbf40?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Granulaat voor orale suspensie",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/dificlir-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Fidaxomicin",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp124456",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CITROENZUUR 0-WATER (E 330)",
    "GLYCEROLTRIACETAAT (E 1518)",
    "KUNSTMATIGE GEMENGDE BESSENSMAAKSTOF",
    "NATRIUMBENZOAAT (E 211)",
    "NATRIUMZETMEELGLYCOLAAT",
    "NATRIUMZETMEELOCTENYLSUCCINAAT (E 1450)",
    "PROPYLEENGLYCOL (E 1520)",
    "STIKSTOF (HEAD SPACE) (E 941)",
    "SUCRALOSE (E 955)",
    "TRINATRIUMCITRAAT 2-WATER (E 331)",
    "XANTHAANGOM (E 415)"
  ],
  "substances": [
    "FIDAXOMICINE"
  ],
  "leaflet_url": null,
  "authorised_at": "2020/02/13",
  "procedure_number": "EMEA/H/C/002087",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/11/733",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about fidaxomicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console